Mercer Global Advisors
CRVS icon

Mercer Global Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Mercer Global Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,550
Closed -$10K – 1942
2023
Q1 		$10K Hold
10,550
– – ﹤0.01% 1914
2022
Q4 		$9K Hold
10,550
– – ﹤0.01% 1915
2022
Q3 		$9K Hold
10,550
– – ﹤0.01% 1806
2022
Q2 		$10K Hold
10,550
– – ﹤0.01% 1812
2022
Q1 		$17K Hold
10,550
– – ﹤0.01% 1857
2021
Q4 		$25K Buy
10,550
+50
+0.5% +$194 ﹤0.01% 1779
2021
Q3 		$51K Hold
10,500
– – ﹤0.01% 1720
2021
Q2 		$28K Hold
10,500
– – ﹤0.01% 1654
2021
Q1 		$32K Buy
+10,500
New +$37.9K ﹤0.01% 1595

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return